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To the Editor: Tularemia is a zoonosis caused by the 
bacterium Francisella tularensis; the main forms of disease 
that occur in humans are ulceroglandular/glandular, oculo-
glandular, oropharyngeal, and respiratory. In Turkey, tula-
remia outbreaks were described as early as 1936–1938 (1), 
but tularemia was not reportable until 2004. Recently, mul-
tiple tularemia outbreaks in Turkey have been described, 
including in regions where the disease has not been previ-
ously reported; it is now considered a reemerging zoonotic 
disease in Turkey (1).
The only F. tularensis subspecies found in most of Eur-
asia, including Turkey, is holarctica. Genetic diversity is 
low, probably because emergence is recent (2). However, 
discovery of whole-genome single-nucleotide polymor-
phisms (SNPs), coupled with subsequent canonical SNP 
(canSNP) analyses, have identified numerous phylogenet-
ic groups within this subspecies.  The distinct phylogeo-
graphic patterns provide insight into its evolutionary his-
tory (3–7).
From December 2009 through January 2011, tulare-
mia outbreaks increased in Turkey, primarily in the cen-
tral region (8). Oropharyngeal tularemia was diagnosed for 
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Table. Francisella tularensis–positive clinical samples from 14 
patients with oropharyngeal tularemia, Turkey, December 2009–
January 2011* 
Patient no.  





1 (F0737) Corum B.20/21/33 i 
2 (F0738) Cankırı B.28/29 b 
3 (F0739) Yozgat B.28/29 b 
4 (F0740) Zonguldak B.7/8 a 
5 (F0741) Corum B.20/21/33 e 
6 (F0742) Corum B.20/21/33 e 
7 (F0743) Corum B.20/21/33§ ND 
8 (F0744)¶ Bala/Ankara B.20/21/33 e 
9 (F0745) Ankara B.20/21/33 d 
10 (F0746) Corum B.20/21/33 j 
11 (F0747) Bala/Ankara B.20/21/33 g 
12 (F0748) Corum B.20/21/33 f 
13 (F0749) Ankara B.20/21/33 c 
14 (F0750) Emirdağ/Afyon B.20/21/33 h 
*Clinical samples collected in 2011 from patients with cervical 
lymphadenitis at Hacettepe University Medical Faculty, Pediatric Infectious 
Disease unit, Ankara, Turkey. CanSNP, canonical single-nucleotide 
polymorphism; MLVA, multilocus variable-number tandem-repeat analysis; 
ND, not determined. 
†Subgroups published in (3,4,6,7). CanSNP branches tested on samples 
in this study: B.3, B.4, B.5, B.6, B.7, B.8, B.9, B.10, B.11, B.13, B.20, B.21, 
B.22, B.26, B.27, B.28, B.29, B.30, B.31, B.32, and B.33. 
‡MLVA markers (M03, M05, M06, M20) (2). 
§Subgroup classification based on approximation because genotype for 
B.33 remains unresolved. 
¶This patient was an adult (all others were children). 
 
14 patients (13 children, 1 adult), and fine-needle lymph 
node aspiration was performed at the Pediatric Infectious 
Diseases Unit at Hacettepe University, Ankara. DNA was 
extracted from these 14 samples (QIAamp DNA Mini Kit; 
QIAGEN, Hilden, Germany) and screened by using a PCR 
selective for the tul4 gene region specific to F. tularensis 
(9); all 14 samples were positive for F. tularensis (Table). 
Residual, de-identified portions of these 14 DNA extracts 
were used for this study.
Genetic characterization led to assignment of these 
14 samples to multiple phylogenetic groups within F. tu-
larensis subsp. holarctica. Analysis with 18 previously de-
scribed (3,4,6,7) canSNP assays (Table) led to assignment 
of the 14 samples to 3 previously described phylogenetic 
groups within this subspecies: B.20/21/33 (n = 11), B.28/29 
(n = 2), and B.7/8 (n = 1) (Table; online Technical Ap-
pendix, http://wwwnc.cdc.gov/EID/article/21/1/14-1087-
Techapp1.pdf). To identify additional genetic diversity, we 
used 4 previously described (2) variable-number tandem-
repeat markers (M03, M05, M06, and M20) and identified 
10 genotypes among the 14 samples, 8 of which were iden-
tified in the 11 B.20/21/33 samples (Table). 
The genetic diversity among these samples and their 
widespread geographic origins from 6 provinces in central 
Turkey (Table; online Technical Appendix) suggest that 
the patients contracted tularemia from multiple indepen-
dent sources. These sources might have been contaminated 
drinking water, which has been implicated as the source of 
human tularemia in previous outbreaks in Turkey (1) and 
could account for oropharyngeal tularemia in the 14 pa-
tients reported here.
The finding of these 3 phylogenetic groups within Tur-
key expands the known geographic range of these phylo-
genetic groups within F. tularensis subsp. holarctica. The 
presence of group B.28/29 F. tularensis in Turkey is not 
surprising; isolates belonging to this group were previously 
identified in bordering Georgia (3). Likewise, the presence 
of group B.20/21/33 F. tularensis is not unexpected, given 
the wide geographic distribution (Sweden, Finland, Rus-
sia, and Hungary [4]) of organisms belonging to this group 
(online Technical Appendix). Isolating group B.7/8 F. tula-
rensis, previously thought to occur only in Scandinavia, in 
Turkey is of particular interest, given the relatively basal 
position of this group in the F. tularensis subsp. holarctica 
phylogeny (online Technical Appendix). Indeed, descen-
dants of this group have, to date, been identified from North 
America only, suggesting a transfer from the Old World to 
the New World within this lineage (7). The circumstances 
of this transfer are unknown but might be discerned through 
additional knowledge of the geographic extent and genetic 
diversity of organisms in the B.7/8 group.
It has been suggested that Scandinavia might be the 
source of the historical spread of tularemia to the rest of 
Europe and might be the origin of the ancestor to the B.13 
clade (5). This suggestion was previously argued because 
F. tularensis subsp. holarctica isolates from Sweden have 
yielded more phylogenetic diversity than isolates from any 
other country. Indeed, except for the B.27 clade, much of 
the known phylogenetic diversity of this organism within 
Europe is present in Sweden (5). Some of the largest sets 
of analyzed samples originated in Sweden (5–7), whereas 
eastern Europe and much of Asia remain mostly undersam-
pled. The high genetic diversity identified in our very lim-
ited sample set from Turkey is notable and includes 2 major 
lineages (B.7 and B.13; online Technical Appendix). These 
findings, together with the recent discovery that organisms 
of multiple F. tularensis subsp. holarctica phylogenetic 
groups exist in China (10), suggest that much additional 
phylogenetic diversity within this subspecies remains to be 
discovered in Eurasia, which will provide better informa-
tion about the evolutionary history and historical spread of 
F. tularensis subsp. holarctica.
We have demonstrated that high-resolution genetic 
characterization of F. tularensis DNA extracted from 
biopsy samples is possible, and we conclude that oro-
pharyngeal human tularemia in Turkey is caused by or-
ganisms of multiple distinct phylogenetic groups within 
this subspecies. This pattern, together with the wide 
geographic distribution of the 14 patients within Turkey 
(online Technical Appendix), suggests that the persons 
infected by F. tularensis during the 2009–2011 outbreaks 
in Turkey obtained their infections from multiple environ-
mental sources.
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To the Editor: Dengue virus (DENV) is a member of 
the family Flaviviridae, genus Flavivirus, and comprises 
4 serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). 
DENV is transmitted by Aedes spp. mosquitoes in subtropi-
cal and tropical countries; an estimated 390 million dengue 
infections occurred worldwide in 2010 (1). In Africa, locally 
acquired dengue cases have been reported from 22 countries 
during 1960–2010, and there is evidence of transmission in 
34 countries (2). The burden of dengue in Africa was recently 
estimated to be in the same range as that in Latin America (1).
In 2013, a 71-year-old man came to the Tropical Medi-
cine Clinic at Heidelberg University Hospital (Heidelberg, 
Germany) with suspected dengue fever 3 days after return-
ing from West Africa to Germany. The patient had traveled 
for ≈6 weeks from mid-September through mid-October 
2013 to Togo (Lomié, first 3 weeks), Benin (Ouidah, 1 
week), back to Togo (Lomié, 1 week), and Burkina Faso 
(Ouagadougou, 3 days).
Tests results for DENV nonstructural protein 1 and 
IgM against DENV were positive. The result of a real-time 
reverse transcription PCR for DENV 1–4 was also positive. 
A serotype-specific real-time reverse transcription PCR 
identified DENV-3 (3,4).
To obtain the sequence of a 1,479-nt fragment of the 
complete gene of the envelope glycoprotein gene, we de-
signed generic primers specific for all complete DENV-
3 genomes available from GenBank (alignment was 
performed by using Geneious version 6.1; http://www.
geneious.com), which were then sequentially adapted 
to sequences obtained (primers and protocol available 
upon request). Sequencing of the complete envelope 
glycoprotein gene of the virus isolated from the patient 
identified DENV-3 genotype III (GenBank accession 
no. KJ922394).
For phylogenetic comparison, we chose all DENV-3 
sequences available from Africa and neighboring regions 
and a set of global sequences that represented different gen-
otypes; DENV-1 was used an outgroup. Sequences were 
aligned on the basis of translated nucleotide sequences, and 
a neighbor-joining tree with p-distance was inferred with 
1,000 bootstrap replicates in MEGA version 5.2.1 (http://
www.megasoftware.net/) for a 1,479-nt fragment span-
ning the complete gene of the envelope glycoprotein and a 
smaller fragment of 220 nt (Figure). We observed cluster-
ing of the virus sequence with those of strains from Côte 
d’Ivoire and Benin. Genetic identity was 99% with strains 
from Côte d’Ivoire (AB447989) (1,472/1,479 nt) and Be-
nin (AB690858) (1,469/1,479nt).
Because of limited availability of only 4 complete 
envelope glycoprotein gene sequences from Africa, an 
additional phylogenetic analysis was performed with a 
smaller fragment of 220 nt to include more sequences of 
African origin. A total of 7 sequences, including additional 
sequences from Senegal and Cameroon, were available. 
Clustering of sequences of African origin was confirmed 
in this analysis; highest sequence identity of virus isolated 
from the patient was with viruses isolated in Côte d’Ivoire, 
Benin, and Senegal.
Nearly all sequence data for DENV-3 from Africa 
originate from returning travelers, such as reports of im-
ported cases in 2006 from Cameroon to Spain (5), from 
Senegal to Spain in 2007 and to Italy in 2010 (5,6), from 
Côte d’Ivoire to France and Japan in 2008 (7,8), from Be-
nin to Japan and France in 2010 (8,9), and from Eritrea to 
Finland in 2010 (5). Phylogenetic analysis of virus strains 
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